Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 09 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

New algorithm predicts acute liver failure in drug-induced liver injury

This month's issue of Gastroenterology examines the use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

News image

Hy's Law, which states that hepatocellular drug-induced liver injury with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure.

Dr Isabel Lucena and colleagues from Spain optimized the definition of Hy's Law, and developed a model for predicting acute liver failure in patients with drug-induced liver injury.

The researchers collected data from 771 patients with drug-induced liver injury from the Spanish DILI registry, from 1994 through 2012.

The team analyzed data collected at drug-induced liver injury recognition, and at the time of peak levels of alanine aminotransferase (ALT) and total bilirubin.

Of the 771 patients with drug-induced liver injury, 32 developed acute liver failure.

Hepatocellular injury, female sex, high levels of total bilirubin, and a high ratio of aspartate aminotransferase (AST):ALT were independent risk factors for acute liver failure.

An R-based model identified patients who developed acute liver failure with 67% specificity
Gastroenterology

The research team compared 3 ways to use Hy's Law to predict which patients would develop acute liver failure.

All included total bilirubin greater than 2-fold the upper limit of normal (×ULN), and either ALT level greater than 3 × ULN, a ratio (R) value of 5 or greater, or a new ratio (nR) value of 5 or greater.

At recognition of drug-induced liver injury, the R- and nR-based models identified patients who developed acute liver failure with 67% and 63% specificity, respectively, whereas use of only ALT level identified them with 44% specificity.

However, the level of ALT and the nR model each identified patients who developed acute liver failure with 90% sensitivity, whereas the R criteria identified them with 83% sensitivity.

The team found an equal number of patients who did and did not develop ALF had alkaline phosphatase levels greater than 2 × ULN.

The researchers observed that an algorithm based on AST level greater than 17.3 × ULN, total bilirubin greater than 6.6 × ULN, and AST:ALT greater than 1.5 identified patients who developed acute liver failure with 82% specificity and 80% sensitivity.

Dr Lucena's team concludes, "When applied at drug-induced liver injury recognition, the nR criteria for Hy's Law provides the best balance of sensitivity and specificity whereas our new composite algorithm provides additional specificity in predicting the ultimate development of acute liver failure."

Gastroenterol 2014: 147(1): 109–118.e5
03 July 2014

Go to top of page Email this page Email this page to a colleague

 09 February 2016 
Cancer-specific prognosis in octogenarians with colorectal cancer
 09 February 2016 
Eosinophilic esophagitis and parental allergies
 09 February 2016 
Bowel preparation for colonoscopy screening
 08 February 2016 
Immunity in the human gut
 08 February 2016 
Cancelled colonoscopy appointments
 08 February 2016 
Cognitive function in Crohn's disease
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Methotrexate and remission in ulcerative colitis
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 01 February 2016 
Managing HBV in pregnancy
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's
 15 January 2016 
Alcohol- and HCV-related hepatocellular carcinoma
 15 January 2016 
Recurrent colonic diverticulitis
 15 January 2016 
Colonic diverticula and colorectal cancer risk
 14 January 2016 
Risk stratification of incidentally discovered gallstones
 14 January 2016 
Treatment of refractory cholestatic pruritus
 14 January 2016 
Colonic diverticula and colorectal cancer risk 
 13 January 2016 
C-section delivery and IBD risk
 13 January 2016 
Primary biliary cholangitis treatment with incomplete UDCA response
 13 January 2016 
Colon cancer screening rates 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us